EGFR and lung cancer: Unexpectedly, the initial trials of EGFR TKIs identified higher ORR and improved outcomes among young women, non-smokers, and Asians with lung cancer [7,8], reflecting the fact that the frequency of EGFR mutations is higher in these patient groups.